Expression of CD44 in primary lung carcinomas using histological and cytological analyses

Anticancer Research

Volumn 23, Issue 1 A, 2003, Pages 115-121

  Shimbori, Masumi ^a,c   Kijima, Hiroshi ^a,b   Sato, Sakiyo ^a   Yoshida, Hiromi ^a   Sato, Tadamitsu ^a   Terasaki Fukuzawa, Yasuko ^a   Onoda, Noboru ^a   Kanabuchi, Kazuo ^a   Abe, Yoshiyuki ^b   Nakamura, Masato ^b   Hattori, Manabu ^c   Ohno, Eiji ^c   Kuramoto, Hiroyuki ^c  

^a Yamato Municipal Hospital   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KITASATO UNIVERSITY   (Japan)

Author keywords

CD44; Cytology; Immunohistochemistry; Lung carcinoma

Indexed keywords

HERMES ANTIGEN; ISOPROTEIN;

ARTICLE; CANCER INVASION; CYTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG ADENOCARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPUTUM; TUMOR CELL;

ANTIGENS, CD44; CELL MEMBRANE; GLYCOPROTEINS; HUMANS; LUNG NEOPLASMS; PROTEIN ISOFORMS;

EID: 0037233630     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Sneath RJ and Mangham DC: The normal structure and function of CD44 and its role in neoplasia. Mol Pathol 51: 191-200, 1998.
2. Rudzki Z and Jothy S: CD44 and the adhesion of neoplastic cells. Mol Pathol 50: 57-71, 1997.
3. Naot D, Sionov RV and Ish-Shalom D: CD44: structure, function, and association with the malignant process. Adv Cancer Res 71: 241-319, 1997.
4. Borland G, Ross JA and Guy K: Forms and functions of CD44. Immunology 93: 139-148, 1998.
5. Gunthert U, Hofmann M, Rudy W, Reber S, Zoller M, Haussmann I, Matzku S, Wenzel A, Ponta H and Herrlich P: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65: 13-24, 1991.
6. Herrlich P, Pals S and Ponta H: CD44 in colon cancer. Eur J Cancer 31A: 1110-1112, 1995.
7. Isozaki H, Ohyama T and Mabuchi H: Expression of cell adhesion molecule CD44 and sialyl Lewis A in gastric carcinoma and colorectal carcinoma in association with hepatic metastasis. Int J Oncol 13: 935-942, 1998.
8. Yu Q, Toole BP and Stamenkovic I: Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. J Exp Med 186: 1985-1996, 1997.
9. Pirinen R, Hirvikoski P, Bohm J, Kellokoski J, Moisio K, Viren M, Johansson R, Hollmen S and Kosma VM: Reduced expression of CD44v3 variant isoform is associated with unfavorable outcome in non-small cell lung carcinoma. Hum Pathol 31: 1088-1095, 2000.
10. Hirata T, Fukuse T, Naiki H, Hitomi S and Wada H: Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic factor. Cancer Res 58: 1108-1110, 1998.
11. Tran TA, Kallakury BV, Sheehan CE and Ross JS: Expression of CD44 standard form and variant isoforms in non-small cell lung carcinomas. Hum Pathol 28: 809-814, 1997.
12. Fasano M, Sabatini MT, Wieczorek R, Sidhu G, Goswami S and Jagirdar J: CD44 and its v6 spliced variant in lung tumors: a role in histogenesis? Cancer 80: 34-41, 1997.
13. Terasaki-Fukuzawa Y, Kijima H, Suto A, Takeshita T, Iezumi K, Sato S, Yoshida H, Sato T, Shimbori M and Shiina Y: Decreased nm23 expression, but not Ki-67 labeling index, is significantly correlated with lymph node metastasis of breast invasive ductal carcinoma. Int J Mol Med 9: 25-29, 2002.
14. Yoshida H, Kijima H, Terasaki Y, Suto A, Takeshita T, Omiya H, Shimojima K, Shimbori M, Sato T, Sato S, Onoda N, Yamazaki H, Tamaoki N, Ueyama Y and Nakamura M: Heterogeneous expression of nm23 gene product as a predictor of lymph nodal status in human breast cancer. Int J Oncol 13: 1141-1146, 1998.
15. Sato T, Kijima H, Suto A, Sato S, Yoshida H, Terasaki-Fukuzawa Y, Shimbori M, Onoda N, Osamura RY and Takeshita T: Bcl-2 expression in breast cancer is down-regulated by trans-arterial administration of chemotherapeutic agents. Oncol Rep 8: 1019-1022, 2001.
16. International Union Against Cancer: TNM Classification of Malignant Tumours, 1997, pp. 19-32.
17. World Health Organization: International Histological Classification of Tumours: Histological Typing of Lung and Pleural Tumours. Springer: Genova, 1981, pp. 31-44.
18. Sing A, Freudenberg N, Kortsik C, Wertzel H, Klosa B and Hasse J: Comparison of the sensitivity of sputum and brush cytology in the diagnosis of lung carcinomas. Acta Cytol 41: 399-408, 1997.
19. Ng AB and Horak GC: Factors significant in the diagnostic accuracy of lung cytology in bronchial washing and sputum samples. II. Sputum samples. Acta Cytol 27: 397-402, 1983.
20. Sy MS, Mori H and Liu D: CD44 as a marker in human cancers. Curr Opin Oncol 9: 108-112, 1997.
21. Bourrguignon LY, Iida N, Welsh CF, Zhu D, Krongrad A and Pasquale D: Involvement of CD44 and its variant isoforms in membrane-cytoskeleton interaction, cell adhesion and tumor metastasis. J Neurooncol 26: 201-208, 1995.
22. Zoller M: CD44 physiological expression of distinct isoforms as evidence for organ-specific metastasis formation. J Mol Med 73: 425-438, 1995.
23. Gunthert U, Stauder R, Mayer B, Terpe HJ, Finke L and Friedrichs K: Are CD44 variant isoforms involved in human tumour progression? Cancer Surv 24: 19-42, 1995.
24. Okamoto I, Morisaki T, Sasaki J, Miyake H, Matsumoto M, Suga M, Ando M and Saya H: Molecular detection of cancer cells by competitive reverse transcription-polymerase chain reaction analysis of specific CD44 variant RNAs. J Natl Cancer Inst 90: 307-315, 1998.
25. Herrlich P, Morrison H, Sleeman J, Orian-Rousseau V, Konig H, Weg-Remers S and Ponta H: CD44 acts both as a growth- and invasiveness-promoting molecule and as a tumor-suppressing cofactor. Ann N Y Acad Sci 910: 106-120, 2000.
26. Tanabe KK and Saya H: The CD44 adhesion molecule and metastasis. Crit Rev Oncog 5: 201-212, 1994.
27. Hofmann M, Rudy W, Gunthert U, Zimmer SG, Zawadzki V, Zoller M, Lichtner RB, Herrlich P and Ponta H: A link between ras and metastatic behavior of tumor cells: ras induces CD44 promoter activity and leads to low-level expression of metastasis-specific variants of CD44 in CREF cells. Cancer Res 53: 1516-1521, 1993.
28. Dohadwala M, Luo J, Zhu L, Lin Y, Dougherty GJ, Sharma S, Huang M, Pold M, Batra RK and Dubinett SM: Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem 276: 20809-20812, 2001.
29. Zawadzki V, Perschl A, Rosel M, Hekele A and Zoller M: Blockade of metastasis formation by CD44-receptor globulin. Int J Cancer 75: 919-924, 1998.
30. Kogerman P, Sy MS and Culp LA: Overexpressed human CD44s promotes lung colonization during micrometastasis of murine fibrosarcoma cells: facilitated retention in the lung vasculature. Proc Natl Acad Sci U S A 94: 13233-13238, 1997.
31. Seiter S, Arch R, Reber S, Komitowski D, Hofmann M, Ponta H, Herrlich P, Matzku S and Zoller M: Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med 177: 443-455, 1993.
32. Nguyen VN, Mirejovsky T, Melinova L and Mandys V: CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance. Neoplasma 47: 400-408, 2000.
33. Mizera-Nyczak E, Dyszkiewicz W, Heider KH and Zeromski J: Isoform expression of CD44 adhesion molecules, Bcl-2, p53 and Ki-67 proteins in lung cancer. Tumour Biol 22: 45-53, 2001.
34. Sasaki JI, Tanabe KK, Takahashi K, Okamoto I, Fujimoto H, Matsumoto M, Suga M, Ando M and Saya H: Expression of CD44 splicing isoforms in lung cancers: dominant expression of CD44v8-10 in non-small cell lung carcinomas. Int J Oncol 12: 525-533, 1998.
35. Wimmel A, Schilli M, Kaiser U, Havemann K, Ramaswamy A, Branscheid D, Kogan E and Schuermann M: Preferential histiotypic expression of CD44-isoforms in human lung cancer. Lung Cancer 16: 151-172, 1997.
36. Tojo N, Inase N, Ichioka M, Miyazato I and Nara N: Differential expression of CD44 splice variants in malignant and benign pleural effusions. Tohoku J Exp Med 179: 273-279, 1996.
37. Wimmel A, Kogan E, Ramaswamy A and Schuermann M: Variant expression of CD44 in preneoplastic lesions of the lung. Cancer 92: 1231-1236, 2001.
38. Takanami I, Takeuchi K and Naruke M: Expression and prognostic value of the standard CD44 protein in pulmonary adenocarcinoma. Oncol Rep 7: 1065-1067, 2000.
39. Fukuse T, Hirata T, Naiki H, Hitomi S and Wada H: Expression of proliferating cell nuclear antigen and CD44 variant isoforms in the primary and metastatic sites of non-small cell lung carcinoma with intrapulmonary metastases. Cancer 86: 1174-1181, 1999.
40. Kondo K, Miyoshi T, Hino N, Shimizu E, Masuda N, Takada M, Uyama T and Monden Y: High frequency expressions of CD44 standard and variant forms in non-small cell lung cancers, but not in small cell lung cancers. J Surg Oncol 69: 128-136, 1998.
41. Carbognani P, Spaggiari L, Romani A, Solli P, Corradi A, Cantoni AM, Petronini PG, Borghetti AF, Rusca M and Bobbio P: Expression of human CD44v6 in non-small cell lung cancer. Eur Surg Res 30: 403-408, 1998.
42. Miyoshi T, Kondo K, Hino N, Uyama T and Monden Y: The expression of the CD44 variant exon 6 is associated with lymph node metastasis in non-small cell lung cancer. Clin Cancer Res 3: 1289-1297, 1997.
43. Penno MB, August JT, Baylin SB, Mabry M, Linnoila RI, Lee VS, Croteau D, Yang XL and Rosada C: Expression of CD44 in human lung tumors. Cancer Res 54: 1381-1387, 1994.